In a 12-week, phase 3 clinical trial
Effective Dyspareunia Relief1,2
IMVEXXY demonstrated statistically significant improvement in moderate to severe dyspareunia due to menopause.1
IMVEXXY reduced moderate to severe dyspareunia due to VVA at week 12 and as early as week 2 (a secondary endpoint) (N=574)1-3
*P<0.05; †P<0.0001.
P value vs placebo based on mixed model repeated measures analysis.
Normal cytology and proper pH levels (commonly known as vaginal pH balance) are important to support vaginal health and microbiome4
IMVEXXY demonstrated efficacy in 3 co-primary endpoints (change in vaginal parabasal and superficial cells and vaginal pH levels)1,2
IMVEXXY is bio-identical* estradiol that is structurally identical to the estrogen produced in the body.2,3,5
*The relevance of risks associated with the use of synthetic hormones compared to bio-identical hormones is not known but cannot be excluded.
For healthcare professionals